



STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, May 19, 2011
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Ellie Brownstein, M.D.

Kort DeLost, R.Ph.

Brandon Jennings, PharmD.

Raymond Ward, M.D.

Beth Johnson, R.Ph.

Karen Gunning, PharmD.

Lisa Hunt, R.Ph.

Dept. of Health/Div. of Health Care Financing Staff Present:

Tim Morley, R.Ph.

Richard Sorenson, R.N.

University of Utah Drug Information Center Staff Present:

Gary Oderda, PharmD.

Melissa Archer, PharmD.

Other Individuals Present:

Esther Estes, Merck

Barry Scott, Merck

Carin Steinvoort, U of U

Efrain Alton, Merck

Jonny Mears, Guest

Nathan Votrubek, U of U

Meeting conducted by: Karen Gunning PharmD., Co-Chairperson.

1. Review and Approval of Minutes: Dr. Ward moved to approve the March 2011 minutes. Kort DeLost seconded the motion. The motion was approved with unanimous votes by Dr. Brownstein, Kort DeLost, Karen Gunning, Lisa Hunt, Beth Johnson, Dr. Flynn, Brandon Jennings, and Dr. Ward.
2. Housekeeping: Lisa Hunt thanked Dr. Ward and Dr. Flynn for their service. Their terms are up and they will be released following the May meeting.
3. DUR Board Update: The DUR Board did not meet in May due to lack of a quorum. During the April meeting, oral multiple sclerosis therapies were reviewed, and the Vivitrol criteria were updated. Coming up, the Board will review Sprycel, Banzel, and adult acne PA criteria.
4. Melissa Archer from the University of Utah presented research on local estrogen replacement products.

Karen Gunning asked if the higher dose vaginal ring should be considered as a local or systemic treatment. Dr. Archer stated that this should probably be considered a systemic treatment, since it is indicated for the treatment of vasomotor symptoms. The higher dose ring is Femring.

Karen asked for public comment.

The first letter was from Intermountain Urological Center, requesting that Premarin vaginal cream remain available.

The second letter was from Jim Kolcher, OBGYN, requesting that Premarin vaginal cream remain available.

Dr. Lori Blackner from Pfizer addressed the Committee in favor of Premarin vaginal cream.

Karen asked if there are DUR quantity limitations, or limits on concomitant use of oral and topical agents for safety. There are no limits on estrogen products.

Karen asked about the accuracy of some of the utilization data. Dr. Archer thought that the columns might be reversed.

Kort stated that lately he has seen more Vagifem than Premarin lately, possibly due to ease of measurement and use (tablet versus a messy cream).

Karen felt that for pediatric issues, there was a clearly established need for cream. Also, the Femring should not be a part of this group because it is systemically absorbed and used for vasomotor symptoms.

Dr. Brownstein moved that the agents are equally safe and efficacious, and that at least one cream should be included. Additionally, the Femring should not be considered part of this class. Dr. Ward seconded the motion. The motion was approved with unanimous votes by Dr. Brownstein, Kort DeLost, Karen Gunning, Lisa Hunt, Beth Johnson, Dr. Flynn, Brandon Jennings, and Dr. Ward.

5. The P&T agenda for the next several months was discussed. In particular, the Committee asked for items that might be helpful in their deliberations for various classes.

Next Meeting Set for Thursday, June 16, 2011

Meeting Adjourned.

Minutes prepared by Jennifer Zeleny